Drug class
Ethyl ester of eicosapentaenoic acid (EPA); omega-3 fatty acid lipid-modifying agent
Mechanism of action
Icosapent ethyl is hydrolysed to EPA. EPA may reduce hepatic very-low-density lipoprotein triglyceride synthesis and/or secretion and enhance triglyceride clearance; additional anti-inflammatory and membrane effects may contribute, but the precise cardiovascular risk-reduction mechanism is not fully established.
General use cases
- Adjunct to maximally tolerated statin therapy to reduce triglyceride levels in adults with severe hypertriglyceridaemia
- Adjunct to statin therapy to reduce risk of myocardial infarction, stroke, coronary revascularisation and unstable angina requiring hospitalisation in eligible adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
